Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Avadel Pharmaceuticals (Nasdaq: AVDL) announced its upcoming participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, May 20 at 12:00 p.m. ET. Investors can access both the live webcast and a 90-day archived recording of the presentation through Avadel's Investor Relations website at investors.avadel.com.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato la sua prossima partecipazione al 3° Annuale BioConnect Investor Conference di H.C. Wainwright. Il team di gestione dell'azienda prenderà parte a una conversazione informale prevista per martedì 20 maggio alle 12:00 ET. Gli investitori potranno seguire la diretta streaming e accedere alla registrazione archiviata per 90 giorni tramite il sito web delle Relazioni con gli Investitori di Avadel all'indirizzo investors.avadel.com.
Avadel Pharmaceuticals (Nasdaq: AVDL) anunció su próxima participación en la 3ª Conferencia Anual BioConnect para Inversores de H.C. Wainwright. El equipo directivo de la empresa participará en una charla informal programada para el martes 20 de mayo a las 12:00 p.m. ET. Los inversores podrán acceder tanto a la transmisión en vivo como a una grabación archivada durante 90 días de la presentación a través del sitio web de Relaciones con Inversores de Avadel en investors.avadel.com.
Avadel Pharmaceuticals (나스닥: AVDL)가 H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사 경영진은 5월 20일 화요일 오후 12시(동부시간)에 예정된 대화형 토론에 참여할 예정입니다. 투자자들은 Avadel의 투자자 관계 웹사이트인 investors.avadel.com을 통해 생중계 웹캐스트와 발표의 90일간 보관된 녹화 영상을 시청할 수 있습니다.
Avadel Pharmaceuticals (Nasdaq : AVDL) a annoncé sa prochaine participation à la 3e conférence annuelle BioConnect pour investisseurs de H.C. Wainwright. L'équipe de direction de la société participera à une discussion informelle prévue pour le mardi 20 mai à 12h00 ET. Les investisseurs pourront accéder à la fois au webinaire en direct et à un enregistrement archivé pendant 90 jours de la présentation via le site des relations investisseurs d'Avadel à l'adresse investors.avadel.com.
Avadel Pharmaceuticals (Nasdaq: AVDL) kündigte seine bevorstehende Teilnahme an der 3. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright an. Das Management-Team des Unternehmens wird an einem Gespräch am Kamin teilnehmen, das für Dienstag, den 20. Mai um 12:00 Uhr ET geplant ist. Investoren können sowohl den Live-Webcast als auch eine 90-tägige Archivaufnahme der Präsentation über die Investor-Relations-Website von Avadel unter investors.avadel.com abrufen.
- None.
- None.
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m. ET.
A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
When is Avadel Pharmaceuticals (AVDL) presenting at the H.C. Wainwright BioConnect Conference?
How can investors access Avadel Pharmaceuticals' (AVDL) presentation at the H.C. Wainwright Conference?
How long will Avadel Pharmaceuticals' (AVDL) H.C. Wainwright Conference presentation be available for replay?
What type of presentation will Avadel Pharmaceuticals (AVDL) give at the H.C. Wainwright Conference?
